<DOC>
	<DOCNO>NCT00530634</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) together radiation therapy surgery may kill tumor cell remain surgery . PURPOSE : This phase II trial study well surgery follow gemcitabine , cisplatin , radiation therapy work treat patient stage II stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Surgery , Gemcitabine , Cisplatin , Radiation Therapy Treating Patients With Stage II Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To assess overall survival progression-free survival patient stage II-IIIB non-small cell lung cancer undergo surgical resection , follow adjuvant chemotherapy comprise gemcitabine cisplatin , radiotherapy . - To assess toxicity regimen patient . - To evaluate mRNA expression enzyme ( i.e. , excision repair cross complement protein , ribonucleotide reductase , cytidine/deoxycytidine deaminase kinase ) , may important regulate cytotoxicity gemcitabine cisplatin patient tumor . - To correlate mRNA level progression-free survival patient treat regimen . - To assess BCL2 , P53 , HER2-neu expression IHC correlation progression-free survival . OUTLINE : Patients undergo surgical resection tumor mediastinal lymph node dissection . Patients complete surgical eradication disease pathologic evidence microscopic residual disease proceed adjuvant chemotherapy . Within approximately 60 day surgical resection , patient receive adjuvant chemotherapy comprise gemcitabine IV 30 minute day 1 8 cisplatin IV 1 hour day 8 . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . Beginning 130-144 day surgery , patient undergo radiotherapy daily , five day week , approximately 6 week . Tumor tissue specimen obtain time surgical resection pharmacodynamic biomarker correlative study . Specimens examine reverse transcriptase-polymerase chain reaction measure mRNA expression target oncogene ( i.e. , DNA repair gene ERCC-1 M2 subunit DNA repair gene ribonucleotide reductase ) enzymes ( i.e. , cytidine/deoxycytidine deaminase kinase ) . Resected specimen also assess IHC expression BCL2 , P53 , HER2-neu gene . After completion study therapy , patient follow every 6 month 5 year annually thereafter .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm single , primary bronchogenic nonsmall cell lung cancer meeting follow subtypes : Adenocarcinoma ( bronchioalveolar cell histology ) Squamous cell carcinoma Large cell carcinoma Meeting follow stag criterion : Stage IIB ( T2 , N1 , M0 , T3 , N0 , M0 ) Stage IIIA ( T13 , N2 , M0 T3 , N1 , M0 ) Stage IIIB ( Any T , N3 , M0 T4 , Any N , M0 ) No 1 parenchymal lesion lung lungs No tumor involve superior sulcus ( e.g. , Pancoast tumor ) Patients must undergo evaluation involve thoracic surgeon , medical oncologist , radiation oncologist prior registration No evidence metastatic disease Biopsy aspiration cytology require confirm benign diagnosis CT MRI abnormalities potentially represent metastatic disease Biopsy require noninvasive test indeterminant PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Absolute granulocyte count ≥ 1,500/μL Platelet count ≥ 100,000/μL Bilirubin ≤ 3 time upper limit normal ( ULN ) SGOT SGPT ≤ 3 time ULN Creatinine clearance &gt; 50 mL/min No prior malignancy except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , ductal lobular carcinoma situ breast , cancer patient diseasefree 5 year Not pregnant nursing Negative pregnancy test Fertile patient must use effective protection No significant hearing loss patient unwilling accept potential hearing loss No uncontrolled medical illness appropriate medical therapy ( e.g. , myocardial infarction within past 3 month liver cirrhosis ) No symptomatic peripheral neuropathy affect activity daily live PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy lung cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>